Christopher DeRenzo, MD, MBA
Christopher DeRenzo, MD, MBA

Christopher DeRenzo, MD, MBA

Assistant Member, St. Jude Faculty

Departments

Education

BA – Rutgers University, New Brunswick, New Jersey
MBA – Rutgers Business School, New Brunswick, New Jersey
MD – Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey
Residency – Case Western Reserve University, Rainbow Babies and Children’s Hospital, Cleveland, Ohio
Fellowship – Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas

Research Interests

  • Adoptive cell therapy for pediatric patients with solid tumors
  • Enhancing CAR T cell effector function in the immunosuppressive tumor microenvironment

Selected Publications

Nguyen P, Okeke E, Clay M, Haydar D, Justice J, O’Reilly C, Pruett-Miller S, Papizan J, Moore J, Zhou S, Throm R, Krenciute G, Gottschalk S, and DeRenzo C. Route of 41BB/41BBL costimulation determines effector function of B7-H3-CAR.CD28ζ T cells. Molecular Therapy–Oncoloytics 18:202-214, 2020. 

Hegde M, Pashankar F, Joseph S, DeRenzo C, Sanber K, Byrd T, Hicks J, Xu M, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Dakhova O, Salsman V, Grilley B, Gee A, Dotti G, Heslop H, Brenner M, Wels W, Gottschalk S, Ahmed N. HER2-specific CAR T cells induce Complete Remission of Bone Marrow Metastatic Rhabdomyosarcoma. Nature Communications 2020.

Cao F, Nguyen P, Hong B, DeRenzo C, Rainusso N, Rodriguez-Cruz T, Wu M, Liu H, Song X, Suzuki M, Wang L, Yustein J, Gottschalk S. Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells. Advances in Cell and Gene Therapy 2020.

DeRenzo C, Gottschalk S. Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s. Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology 1257:109-131, 2020.

DeRenzo C, Gottschalk S. Genetic modification strategies to enhance CAR T cell persistence for patients with solid tumors. Frontiers in Immunology 10:218, 2019.

DeRenzo C, Lam C, Rodriguez‐Galindo C, Rapkin L, Gottschalk S, Venkatramani R. Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinoma. Pediatric Blood & Cancer 66(1):e27469, 2019.

Last update: August 2020

For updates on COVID-19, please read.